nanatinostat

Overview

Nanatinostat is an investigational HDAC inhibitor. It is evaluated in EBV-associated malignancies including nasopharyngeal carcinoma (NPC), where EBV-driven epigenetic dysregulation plays a key pathogenic role.

Evidence in the corpus

• Nanatinostat HDAC inhibitor listed as an investigational agent targeting EBV-driven epigenetic mechanisms in recurrent/metastatic NPC; included in the catalog of molecularly targeted agents evaluated in NPC PMID:24952746.

Resistance mechanisms

Cancer types (linked)

• NPC

Sources

This page was processed by entity-page-writer on 2026-05-11.